Adjuvant Therapy with Dibromodulcitol and BCNU Increases Survival of Adults with Malignant Gliomas. EORTC Brain Tumor Group
Authors
Affiliations
Objective: We tested adjuvant chemotherapy combining dibromodulcitol (DBD) and bischloroethylnitrosourea (BCNU) given postoperatively to adults with newly diagnosed supratentorial malignant gliomas.
Methods: We enrolled 269 patients, 255 of whom were eligible. After surgery, we treated all patients with radiation therapy, using a median dose of 60 Gy given in 30 fractions. After randomization, patients in the chemotherapy group also received (1) six weekly courses, administered during irradiation, of DBD 700 mg/m2 and (2) one to nine (median, four) courses, administered during the first year following radiation therapy, of DBD 1,000 mg/m2 on day 1 and BCNU 150 mg/m2 on day 2, with the course being repeated every 6 weeks.
Results: Patients treated with radiation therapy along with DBD plus BCNU (group 2) had significantly longer survival time (p = 0.044) and time to progression (p = 0.003) than did those treated with radiation therapy alone (group 1). The median survival time was 13.0 months for group 2 and 10.4 months for group 1; the median time to progression was 8.1 months for group 2 and 6.7 months for group 1. The percentage of patients alive at 18 and 24 months was 34% and 21% in group 2 compared with 21% and 12% in group 1.
Conclusion: DBD plus BCNU is an effective adjuvant therapy for malignant glioma.
Sun M, Huang N, Tao Y, Wen R, Zhao G, Zhang X Trials. 2022; 23(1):234.
PMID: 35346332 PMC: 8962067. DOI: 10.1186/s13063-022-06168-1.
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C, Lawrie T, Rogozinska E, Kernohan A, Jefferies S, Bulbeck H Cochrane Database Syst Rev. 2020; 3:CD013261.
PMID: 32202316 PMC: 7086476. DOI: 10.1002/14651858.CD013261.pub2.
Strowd R, Abuali I, Ye X, Lu Y, Grossman S J Neurooncol. 2016; 127(1):165-71.
PMID: 26729269 PMC: 4787612. DOI: 10.1007/s11060-015-2028-2.
Taal W, Bromberg J, van den Bent M CNS Oncol. 2015; 4(3):179-92.
PMID: 25906059 PMC: 6088309. DOI: 10.2217/cns.15.2.
Shonka N, Theeler B, Cahill D, Yung A, Smith L, Lei X J Neurooncol. 2013; 113(2):305-11.
PMID: 23526410 DOI: 10.1007/s11060-013-1116-4.